Nevertheless, with respect to PDAC, finer resolution of A2A and A2B expression in TME, i.e., in cancer vs immune cells, will be required to understand survival curves (see above) and determine whether A2AR is immunosuppressive and will constitute a successful target in ongoing clinical trials (Table 1). This evidence concerns the gene ADORA2A and cancer.